Hightide Biopharma Pty Ltd

This study tested a new medicine called HTD1801 in 367 adults with type 2 diabetes whose blood sugar was not well controlled with metformin alone. Participants received either HTD1801 or the standard drug dapagliflozin to compare how well each lowers blood sugar and whether they …

This study tested an experimental drug called HTD1801 in 408 adults with type 2 diabetes whose blood sugar was not well controlled by diet and exercise alone. Participants received either the drug or a placebo for 24 weeks. The main goal was to see if the drug lowered HbA1c (a me…

This study tested a new medicine called HTD1801 in 551 adults with type 2 diabetes whose blood sugar was not well controlled by metformin alone. Participants received either HTD1801 or a placebo for 24 weeks to see if the drug could lower blood sugar levels safely. The main goal …

This study tested a new medication called HTD1801 in 59 adults with primary sclerosing cholangitis (PSC), a rare liver disease. Participants received either a low dose, a high dose, or a placebo for 18 weeks. The main goal was to see if the drug could lower levels of alkaline pho…